EP08.02-088 Mutational Status of KRAS, STK11 and CDKN2A Genes as Predictors of Response to Antiangiogenic Agents in Non-small Cell Lung Cancer Patients

Lung cancer is the leading cause of cancer deaths worldwide. Antiangiogenic agents have been established as one of the various treatment options for this type of tumor. However, it has not been possible to establish a biomarker that allows the selection of patients who will most benefit from this treatment. Recent publications suggest that the response to antiangiogenic agents is influenced by the presence of KRAS, TP53 or STK11/LKB1 gene mutations. The aim of this study was to establish the relationship between the presence of tumor mutations and the response to antiangiogenic agents.